Movement disorder in ataxia-telangiectasia: Treatment with amantadine Sulfate

Journal of Child Neurology

Volumn 28, Issue 2, 2013, Pages 155-160

  Nissenkorn, Andreea ^a   Hassin Baer, Sharon ^b,c   Lerman, Sheera F ^b   Levi, Yonit Banet ^a   Tzadok, Michal ^a   Ben Zeev, Bruria ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b Sagol Neuroscience Center   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

ataxia telangiectasia; bradykinesia; chorea; N methyl d aspartate; NMDA antagonists

Indexed keywords

AMANTADINE; AMANTADINE SULFATE;

ABDOMINAL PAIN; ABNORMAL INVOLUNTARY MOVEMENT SCALE; ARTICLE; ATAXIA TELANGIECTASIA; CHILD; CHILDHOOD DISEASE; CHOREA; CLINICAL ARTICLE; CONSTIPATION; HEADACHE; HUMAN; INVOLUNTARY MOVEMENT; MOTOR DYSFUNCTION; MYOCLONUS; NAUSEA; PARKINSONISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SCHOOL CHILD; SCORING SYSTEM; SOMNOLENCE; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

ADOLESCENT; AMANTADINE; ANTIPARKINSON AGENTS; ATAXIA TELANGIECTASIA; CHILD; CHILD, PRESCHOOL; DISABILITY EVALUATION; HUMANS; MOVEMENT DISORDERS; NEUROLOGIC EXAMINATION; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84872875498     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073812441999     Document Type: Article

References (34)

1. Lavin M, Gueven N, Bottle S, Gatti R. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull. 2007 ; 81: 129-147
2. Perlman S, Becker-Catania S, Gatti R. Ataxia-telangiectasia: diagnosis and treatment. Semin Pediatr Neurol. 2003 ; 3: 173-182
3. Nissenkorn A, Levi YB, Vilozni D, et al. Neurologic presentation in ataxia-telangiectasia - is small head circumference a hallmark of disease. J Pediatr. 2011 ; 159: 466.e1-471.e1
4. Broccoletti T, Del Giudice E, Amorosi S, et al. Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients. Eur J Neurol. 2008 ; 15: 223-228
5. Broccoletti T, Del Giudice E, Cirillo E, et al. Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia. Eur J Neurol. 2011 ; 18: 564-570
6. Russo I, Cosentino C, Del Giudice E, et al. In ataxia-telangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity. Eur J Neurol. 2009 ; 16: 755-759
7. Luginger E, Wenning GK, Bosch S, et al. Beneficial effects of amantadine on l-DOPA induced dyskinesia in Parkinson disease. Mov Dis. 2000 ; 15: 873-878
8. Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995 ; 45: 1956-1961
9. Botez MI, Botez-Marquard KM, Elie R. Amantadine hydrochloride treatment in heredo-degenerative ataxias: a double blind study. J Neurol Neurosurg Psychiatry. 1996 ; 61: 259-264
10. Verhagen L, Morris M, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002 ; 59: 694-699
11. Magnet MK, Bonelly R, Hapfhammer HP. Amantadine in akinetic-rigid variant of Huntington's disease. Ann Pharmacother. 2004 ; 38: 1194-1196
12. Glezen WP. Indications for amantadine in otherwise healthy children. Pediatr Inf Dis J. 1993 ; 12: 106
13. Patrick PD, Blackman MD, Mabry JL, et al. Dopamine agonists therapy in low-response children following traumatic brain injury. J Child Neurol. 2006 ; 21: 879-885
14. Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to improve neurorecovery in traumatic brain injury: a pilot double-blind randomized trial. J Head Trauma Rehabil. 2002 ; 17: 300-313
15. Donafrancesco R, Calderoni D, Vitiello B. Open-label amantadine in children with attention deficit/hyperactivity disorder. J Child Neurol Adolesc Psychopharmacol. 2007 ; 17: 657-663
16. Mizoguchi M, Yokoo H, Yoshida M, et al. Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-d-aspartate antagonism. Brain Res. 1994 ; 662: 255-258
17. Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci. 2005 ; 25: 3312-3322
18. Trouillars P, Takayanagi T, Hallet M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci. 1997 ; 145: 205-211
19. Martinez-Martin P, Gil-Najel A, Gracia LM, et al. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord. 1994 ; 9: 76-83
20. Psychopharmacol Bull. 1988 ; 24: 781-783
21. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study: clinical global impression of change. Alzheimer Dis Assoc Disord. 1997 ; 11: S22 - S31
22. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995 ; 268: 1749-1753
23. Guo Z, Kozlov S, Lavin MF, et al. ATM activation by oxidative stress. Science. 2010 ; 330: 517-521
24. Cheron G, Servais L, Dan B. Cerebellar network plasticity: from genes to fast oscillation. Neuroscience. 2008 ; 153: 1-19
25. Ogawa M. Pharmacological treatments of cerebellar ataxia. Cerebellum. 2004 ; 3: 107-111
26. Cubo E, Lopez MD, Ceberio JI, et al. Striatal dopamine function in a family with multiple SCA-3 phenotypes. J Neurol. 2011 ; 258: 308-310
27. Hearst SM, Lopez ME, Shao Q, et al. Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation. J Neurochem. 2010 ; 114: 706-716
28. Salvatore E, Varrone A, Crisculo C. Nigrostriatal involvement in ataxia with oculomotor apraxia type1. J Neurol. 2008 ; 255: 45-48
29. Grelak RP, Clark R, Stump JM, Vernier VG. Amantadine-dopamine interaction: possible mode of action in parkinsonism. Science. 1970 ; 169: 203-204
30. Yakimovskii AF, Varshavskaya VM. Neostriatal glutamatergic system is involved in the pathogenesis of picrotoxin induced choreomyoclonic hyperkinesis. Bull Exp Biol Med. 2004 ; 138: 533-536
31. Lipton S. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev. 2006 ; 5: 160-170
32. Ogawa M, Shigeto H. Yamamto T, et al. d-Cycloserine for the treatment of ataxia in spinocerebellar degeneration. J Neurol Sci. 2003 ; 210: 53-56
33. Hassin-Baer S, Korczyn AD, Giladi N. An open trial of amantadine and buspirone for cerebellar ataxia: a disappointment. J Neural Transm. 2000 ; 107: 1187-1189
34. Crawford TO, Mandir AS, Lefton-Greif MA, et al. Quantitative neurologic assessment of ataxia-telangiectasia. Neurology. 2000 ; 54: 1505-1509